EAM
Eagle Asset Management Portfolio holdings
AUM
$19.6B
1-Year Return
41.7%
This Quarter Return
+1.7%
1 Year Return
+41.7%
3 Year Return
+53.51%
5 Year Return
+214.43%
10 Year Return
+692.81%
AUM
$22.1B
AUM Growth
-$1.14B
(-4.9%)
Cap. Flow
-$1.1B
Cap. Flow
% of AUM
-4.97%
Top 10 Holdings %
Top 10 Hldgs %
11.34%
Holding
628
New
31
Increased
162
Reduced
387
Closed
38
Top Buys
| 1 |
AstraZeneca
AZN
|
$88.4M |
| 2 |
XLNX
Xilinx Inc
XLNX
|
$85.5M |
| 3 |
United Parcel Service
UPS
|
$84.9M |
| 4 |
Agilent Technologies
A
|
$83.3M |
| 5 |
DexCom
DXCM
|
$78.1M |
Top Sells
| 1 |
Johnson & Johnson
JNJ
|
$102M |
| 2 |
Royal Caribbean
RCL
|
$99M |
| 3 |
Moderna
MRNA
|
$87.6M |
| 4 |
Eli Lilly
LLY
|
$77.8M |
| 5 |
Norwegian Cruise Line
NCLH
|
$60.4M |
Sector Composition
| 1 | Technology | 26.7% |
| 2 | Healthcare | 19.34% |
| 3 | Industrials | 14.38% |
| 4 | Consumer Discretionary | 11.98% |
| 5 | Financials | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Abbott
ABT
$231B
| $18.4M | 0.08% |
156,163
+603
| +0.4% | +$71.2K |
|
227
Innospec
IOSP
$2.13B
| $18.3M | 0.08% |
217,171
-33,082
| -13% | -$2.79M |
|
228
First Merchants
FRME
$2.37B
| $18.2M | 0.08% |
435,955
-3,698
| -0.8% | -$155K |
|
229
BridgeBio Pharma
BBIO
$10.2B
| $18.1M | 0.08% |
386,716
-119,233
| -24% | -$5.59M |
|
230
Bandwidth Inc
BAND
$473M
| $17.8M | 0.08% |
197,711
+9,584
| +5% | +$865K |
|
231
Tenet Healthcare
THC
$17.3B
| $17.6M | 0.08% |
265,592
-39,130
| -13% | -$2.6M |
|
|
CHX
232
DELISTED
ChampionX
CHX
| $17.5M | 0.08% |
782,324
-234,794
| -23% | -$5.25M |
|
233
Meta Platforms (Facebook)
META
$1.89T
| $17.4M | 0.08% |
51,124
-1,081
| -2% | -$367K |
|
234
John Wiley & Sons Class A
WLY
$2.13B
| $17.3M | 0.08% |
331,777
-95,026
| -22% | -$4.96M |
|
235
Brink's
BCO
$4.78B
| $17M | 0.08% |
268,154
-91,930
| -26% | -$5.82M |
|
236
AeroVironment
AVAV
$11.3B
| $16.9M | 0.08% |
196,072
+30,752
| +19% | +$2.65M |
|
237
Owens & Minor
OMI
$434M
| $16.5M | 0.07% |
527,481
-411,695
| -44% | -$12.9M |
|
|
NVTA
238
DELISTED
Invitae Corporation
NVTA
| $16.4M | 0.07% |
578,179
-404
| -0.1% | -$11.5K |
|
239
Integra LifeSciences
IART
$1.25B
| $16.4M | 0.07% |
239,191
-65,544
| -22% | -$4.49M |
|
240
Graphic Packaging
GPK
$6.38B
| $16.2M | 0.07% |
851,929
-244,201
| -22% | -$4.65M |
|
241
Nice
NICE
$8.67B
| $16M | 0.07% |
56,270
-10,316
| -15% | -$2.93M |
|
242
Helen of Troy
HELE
$587M
| $15.8M | 0.07% |
70,298
-41,864
| -37% | -$9.41M |
|
243
Cohen & Steers
CNS
$3.7B
| $15.6M | 0.07% |
186,327
-52,408
| -22% | -$4.39M |
|
244
Fate Therapeutics
FATE
$116M
| $15.4M | 0.07% |
259,136
-13,630
| -5% | -$808K |
|
245
TG Therapeutics
TGTX
$5.11B
| $15.2M | 0.07% |
458,146
-381,108
| -45% | -$12.7M |
|
246
Kura Oncology
KURA
$713M
| $15M | 0.07% |
800,854
-359
| -0% | -$6.72K |
|
247
MSC Industrial Direct
MSM
$5.14B
| $15M | 0.07% |
186,763
-50,266
| -21% | -$4.03M |
|
248
Pacific Biosciences
PACB
$381M
| $15M | 0.07% |
585,137
-133,884
| -19% | -$3.42M |
|
249
SPX Corp
SPXC
$9.28B
| $14.7M | 0.07% |
275,936
-9,076
| -3% | -$485K |
|
250
Manhattan Associates
MANH
$13B
| $14.6M | 0.07% |
95,181
-62,144
| -40% | -$9.51M |
|